热门资讯> 正文
在对铅药物的同行评审数据进行审查后，MiNK激增
2025-07-11 23:12
- 艾吉纳斯(AGEN) 0
- NantKwest(NK) 0
- 纳比特(NA) 0
- Shares of MiNK Therapeutics (NASDAQ:INKT) climbed over 500% in the morning hours on Friday after the nano-cap cell therapy developer, which is a unit of Agenus (NASDAQ:AGEN), announced peer-reviewed data from a Phase 1 trial for its lead asset, agenT-797, in testicular cancer.
- The upsurge came after the New York-based biotech said that Nature’s Oncogene published a single case of complete remission in a patient with metastatic, treatment-refractory testicular cancer who received agenT-797 in its Phase 1 trial for solid tumors.
- The patient, who had been heavily pretreated, demonstrated a complete clinical, radiologic, and biochemical remission without any signs of disease over two years, the company added.
- According to the publication, the experimental therapy was found to be safe, as the patient didn’t develop cytokine release syndrome or graft-versus-host disease.
More on MiNK Therapeutics, Agenus
- Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide
- MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript
- Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript
- Agenus climbs on deal with India’s Zydus for cancer therapy BOT/BAL
- Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit
推荐文章
美股机会日报 | 特朗普放大招！9万亿养老金即将杀入加密市场；美联储主席候选人支持7月降息
一周财经日历 | 特斯拉、谷歌财报重磅来袭！维立志博将于下周五登陆港交所
一图看懂 | 港股上半年IPO募资额登顶全球！中签就赚一万港币的“大肉签”你参与了吗？
华盛早报丨重大突破！三大加密货币法案众议院闯关成功；美联储，降息大消息
黄仁勋年内三度访华！H20重返中国市场，释放了什么信号？
创新药行情彻底爆发！维立志博-B打新半日孖展超购130倍，冻资近150亿港元
新股申购 | 维立志博-B入场费3535.30港元！引入腾讯、易方达等基石投资者
7月财报预告丨迎关税考验！特斯拉、台积电放榜在即，美股能否守住涨势？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
